Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.9%

3 terminated out of 51 trials

Success Rate

90.6%

+4.1% vs benchmark

Late-Stage Pipeline

20%

10 trials in Phase 3/4

Results Transparency

17%

5 of 29 completed with results

Key Signals

5 with results91% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (10)
Early P 1 (1)
P 1 (4)
P 2 (6)
P 3 (7)
P 4 (3)

Trial Status

Completed29
Recruiting5
Not Yet Recruiting5
Active Not Recruiting4
Unknown4
Terminated3

Trial Success Rate

90.6%

Benchmark: 86.5%

Based on 29 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT07569172Not ApplicableNot Yet Recruiting

Improved Child Nutrition and Development Through Social Transfers

NCT00001281Recruiting

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

NCT06581575Phase 2Active Not Recruiting

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

NCT06864585Not Yet RecruitingPrimary

A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan

NCT07347015Not ApplicableRecruitingPrimary

Prescription Support System for Antimicrobial Use in Belgian Primary Care

NCT07406529Not ApplicableRecruitingPrimary

Fostering Prosocial Preventive Behaviours Through Awe

NCT07054320Active Not RecruitingPrimary

Rapamycin and Infection-related Illness

NCT07029932Phase 1RecruitingPrimary

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers

NCT07176247Enrolling By Invitation

Real-world Multicentre Study of AZtreonam-AVIbactam Treatment With Infections or Suspected Infections Caused by Multidrug-resistant Gram-negative Bacteria

NCT06762002Recruiting

Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort

NCT07048301Not ApplicableNot Yet RecruitingPrimary

Omaha System-Based Health Application on Improving Knowledge, Attitude, and Behaviors Regarding Infectious Disease Prevention in the Community

NCT06431217Completed

Group B Strep Correlates of Protection Study

NCT06722131Not Yet RecruitingPrimary

Biobank of Samples From Patients With Infectious Diseases

NCT06697379Active Not Recruiting

Key Technology Research and Application Demonstration of Individual Protective Equipment for High-Level Biosafety Laboratories

NCT02654210Active Not RecruitingPrimary

LoewenKIDS - Infections and the Development of the Immune System

NCT05942820Phase 1TerminatedPrimary

The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers

NCT02763345Not ApplicableCompletedPrimary

The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi

NCT05088421Phase 1CompletedPrimary

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers

NCT04182425Completed

Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk for Dysbiosis

NCT05654090Phase 4UnknownPrimary

Evaluate Bioequivalence of Burotam (1/1 g/Vial)

Scroll to load more

Research Network

Activity Timeline